Dynavax Technologies Corporation announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization in Great Britain for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The approval was based on the positive benefit-risk for HEPLISAV B as demonstrated by the safety and immunogenicity results of three Phase 3 clinical trials. The approval was issued to Dynavax's affiliate Dynavax GmbH via the European Commission Decision Reliance Procedure (ECDRP).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.1 USD | +0.95% | -4.72% | -20.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.60% | 1.44B | |
+7.63% | 111B | |
+11.32% | 106B | |
-12.35% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.69% | 16.81B | |
+38.54% | 12.54B | |
-24.35% | 8.09B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine